PDCD1 and glioblastoma: PD-1 blockade yielded promising results in many cancers, and the Ivy Consortium initiated a multiinstitution, randomized, open-label pilot study of pembrolizumab, an anti-PD-1 monoclonal antibody, in patients with recurrent GBM (51).